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Abstract
Purpose Colorectal cancer (CRC) survivors who remain fa-
tigued during long-term follow-up are at risk for worse health
outcomes and need relevant interventions most. The aim of
this study is to prospectively assess cancer-related fatigue
(CRF) and four categories of CRF correlates (clinical charac-
teristics, demographic characteristics, behavior/well-being,
functional status).
Methods CRC survivors diagnosed between 2000 and 2009,
as registered in the population-based Eindhoven Cancer
Registry, completed the Fatigue Assessment Scale at three
annual time points. Linear mixed models were used to assess
the course of CRF and identify its correlates.
Results CRF levels were relatively stable over time. Being
female, young (≤65 years of age), and single; having a low
educational level; treatment with chemotherapy; and having
one or more comorbid conditions were associated with higher
CRF scores. Years since diagnosis, radiotherapy, and disease
stage were not related to CRF over time.
Significant between- and within-subject effects were found
for all well-being factors (social, emotional, and cognitive
functioning, and global quality of life), symptoms (anxiety,
depression, pain, and insomnia), and functional status (phys-
ical and role functioning, physical activity levels) in relation to
CRF.
The differences in CRF levels could, for a large part, be
attributed to differences in behavior/well-being (59 %), func-
tional status (37%), and, to a lesser extent, to sociodemographic
(4 %) and clinical characteristics (8 %).
Conclusion This study showed that sociodemographic and
clinical factors were associated with CRF levels over time
among CRC survivors; however, behavior/well-being and
functional status explained a larger part of the variance in
levels of CRF.
Keywords Behavior . Cancer . Fatigue . Functional status .
Survivorship .Well-being
Introduction
Improvements in early detection and treatment have increased
colorectal cancer (CRC) survival rates [1]. In the Netherlands,
there were about 77,000 CRC survivors in 2009, which is
expected to increase to 121,000 in 2020 [2]. The majority
(>56%) of the CRCpatients survive relatively long (>10 years
after diagnosis) [3]. Despite these advancements, cancer treat-
ments may put cancer survivors at risk for long-term side
effects. With more patients surviving longer, the long-term
effects of cancer and its treatment on the survivors’ well-
being are of increasing importance.
An important long-term effect of cancer and its treatment is
cancer-related fatigue (CRF). CRF is defined as a subjective
sense of physical, emotional, and/or cognitive tiredness or
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exhaustion that is not proportional to recent activity and inter-
feres with usual functioning [4]. CRF is the most common
symptom experienced by cancer survivors, with prevalence
rates of up to 99 % among survivors directly after diagnosis
and during treatment [5]. Among CRC survivors, prevalence
rates range from 41 % among short-term survivors (<5 years
since diagnosis) and 35 % among long-term survivors
(≥5 years since diagnosis) [6]. Cancer survivors indicate that
CRF ismore troublesome and has a greater negative impact on
health-related quality of life (HRQoL) and daily activities than
other distressing cancer symptoms, like pain and depression
[7]. Given the high prevalence and impact of CRF, it is an
important target for identification and treatment.
The causes underlying CRF are still not well understood.
However, it is hypothesized that CRF is rooted in both biology
and behavior [8]. In a recent recommendation paper, a con-
ceptual framework was proposed whereby five categories of
CRF correlates were identified: clinical characteristics (e.g.,
disease stage, treatment), demographic characteristics (e.g.,
age, sex), behavior/well-being (e.g., anxiety, pain), functional
status (e.g., performance status), and biologic status (e.g., cy-
tokine function) [8]. Although studies show that prevalence
rates of CRF diminish during post-treatment follow-up, more
insight is needed into the longitudinal course of CRF during
long-term survivorship and the correlates that contribute to
CRF over time. Survivors who remain fatigued during long-
term follow-up are at risk for worse health outcomes and need
relevant interventions most [8]. To achieve personalized man-
agement of CRF, insight into the correlates of CRF among
long-term survivors is needed to identify subgroups of survi-
vors at risk of remaining fatigued and also the correlates for
intervention. Therefore, the aim of this study is to prospectively
assess CRF and its correlates among CRC survivors. An
adapted version of the conceptual CRF correlates framework
will be used for our study (Fig. 1). We have not included the
biological status dimension of the original model in our study,
as the Patient Reported Outcomes Following Initial treatment
and Long term Evaluation of Survivorship (PROFILES) regis-
try currently does not collect biological data.
Methods
Setting and population
This study is part of a longitudinal, population-based survey
among CRC survivors registered within the Eindhoven
Cancer Registry (ECR) of the Comprehensive Cancer Centre
Netherlands. The ECR records data on all individuals who are
newly diagnosed with cancer in the southern part of the
Netherlands, an area with 2.3 million inhabitants, 18 hospital
locations, and two large radiotherapy institutes. All individ-
uals diagnosed with CRC between 2000 and 2009 as regis-
tered in the ECR were eligible for participation. Survivors
who had died prior to start of the study (according to the
Central Bureau for Genealogy which collects information on
all deceased Dutch citizens via the civil municipal registries
and hospital records) or had unverifiable addresses were ex-
cluded. Also, survivors with severe cognitive impairment
(e.g., dementia) were excluded because it was expected that
they would have difficulties completing the questionnaires
without assistance. The study started in December 2010
(T1), and respondents received a subsequent questionnaire in
2011 (T2) and 2012 (T3). A complete overview of the
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Fig. 1 Correlates of cancer-related fatigue
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selection of survivors can be found in Fig. 2. Ethical approval
for the study was obtained from a local certified Medical
Ethics Committee of the Maxima Medical Centre
Veldhoven, the Netherlands.
Data collection
Data collection was done within PROFILES. PROFILES is a
registry for the study of the physical and psychosocial impact
of cancer and its treatment from a dynamic, growing
population-based cohort of both short- and long-term cancer
survivors. PROFILES contains a large web-based component
and is linked directly to clinical data from the ECR. Details of
the data collection method were previously described [9].
Study measures
Fatigue
CRFwas assessed with the Fatigue Assessment Scale (FAS), a
questionnaire consisting of ten items. The response scale is a
five-point scale (1 never to 5 always), and total scores can
Fig. 2 Flow chart of the study
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range from 10 to 50. Survivors can be divided into two groups
based on total FAS scores [10]: not fatigued (as defined by a
score of 10 to 21) and fatigued (22 to 50). The psychometric
properties are good [11].
Clinical characteristics
Clinical information was available from the ECR that routine-
ly collects data on tumor characteristics, including date of
diagnosis, tumor stage, primary treatment, and survivors’
background characteristics. Comorbidity at the time of survey
was assessed with the adapted Self-Administered
Comorbidity Questionnaire (SCQ) [12]. Questions on height
and weight were added to the questionnaire to calculate body
mass index (BMI).
Sociodemographic characteristics
Questions on marital status and educational level were added
to the questionnaire.
Behavior/well-being
Well-being (or HRQoL) was measured by the Dutch version
of the validated European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire-Core 30
(EORTCQLQ-C30) [13]. This 30-itemHRQoL questionnaire
consists of five functional scales, of which only the emotional,
social, and cognitive functioning scales were used in this
study, a global health status scale, three symptom scales, and
single symptom items (only the insomnia and pain items will
be used). Answer categories range from one (not at all) to four
(very much). All scales are linearly transformed according to
the guidelines of the EORTC [13], to reach a scale range of 0
to 100. A higher score on the functional scales and global
quality of life implies better HRQoL, while a higher score
on the symptom scales and items implies more symptoms.
Symptoms of anxiety and depression were assessed with
the Hospital Anxiety and Depression Scale (HADS), with
seven items each for assessing both anxiety and depression
[14]. All items were scored on a zero- to three-point scale,
with higher scores indicating more symptoms. A sum score
was calculated for both scales, which can range from 0 to 21.
Functional status
Functional status was assessed with the physical and role
functioning scales of the EORTC QLQ-C30 [13] and a self-
designed question on employment status which was added to
the questionnaire.
Physical activity level as a dimension of functional status was
assessed with questions derived from the validated European
Prospective Investigation into Cancer (EPIC) Physical Activity
Questionnaire [15]. Survivors were asked how much time they
spend on the following activities (average number of hours per
week (h/week), in summer and winter separately): walking, bi-
cycling, gardening, housekeeping, and sports. Six separate
sports could be specified. Total PAwas calculated by summing
hours/week of all activities. To include an estimate of intensity,
metabolic equivalent intensity values (MET) were assigned to
each activity, according to the compendium of physical activities
[16, 17]. The duration of moderate to vigorous physical activity
(MVPA) was assessed as time (h/week) spent on walking, bicy-
cling, gardening, and sports (≥3MET), excluding housekeeping
and light intensity sports (<3 MET).
Statistical analyses
Differences in sociodemographic and clinical variables be-
tween respondents and non-respondents were examined with
analysis of variance (ANOVA) for continuous variables and
chi-square tests for categorical variables, where appropriate.
Potential non-response bias during follow-up was assessed by
comparing the characteristics of survivors who responded to
all three waves (full respondent), with those who responded to
either two or one data wave. All further analyses were based
on survivors who responded to all three waves.
The course of CRF and the individual associations between
each independent variable and CRF over time were analyzed
using linear mixed models (covariance pattern model with an
unstructured error covariance matrix and maximum likelihood
estimation) [18]. This technique uses data efficiently by also
including incomplete cases in the analyses. As a result of this,
bias is limited and statistical power is preserved. Linear mixed
models were used to adjust for the dependence of observa-
tions. In order to correctly interpret all model parameters, all
continuous variables were grand mean centered [18, 19]. Time
was analyzed as a regular categorical predictor with three
levels (i.e., three time points). Sociodemographic and clinical
variables were analyzed as time-invariant predictors (i.e.,
baseline characteristics were used).
In the first step, we developed a longitudinal linear mixed
model by putting CRF as a dependent variable in the regres-
sion equation and one variable of interest, time, and the pos-
sible confounders as independent variables. Confounders
were chosen based on a priori assumptions: age, gender, hav-
ing a partner, educational level, years since diagnosis, disease
stage, treatment, and number of comorbidities. The con-
founders were also assessed for their association with CRF.
In the second step of the longitudinal data analyses, we
examined the between-subject and within-subject effects for
each continuous independent variable separately. Differences
in CRF can occur because survivors differ in the independent
variable (between-subject) or because a survivor differs over
time in the independent variable (within-subject). Therefore,
the between-subject estimate determined if differences in the
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independent variable between survivors resulted in differ-
ences in CRF. This estimate was represented by survivors’
average amount of CRF reported during the study across the
three measurements. The within-subject estimate determined
causal relations by assessing if changes in the independent
variable within a participant were related to changes in CRF
and was represented by the difference between survivors’
CRF at a certain point in time and his/her average CRF during
the study. The between-subject and within-subject estimates
were simultaneously entered in the linear mixed models to-
gether with the possible confounders and two dummies for
time, with T1 as reference category, as independent variables
and CRF as dependent variable.
Furthermore, cross-sectional multivariate linear regression
analyses were used to assess the conjoint association between
multiple independent variables and CRF at T1. The explained
variance at T1 was assessed for the following domains:
sociodemographic factors, clinical factors, behavior/well-be-
ing, and functional status. Linear regression analyses were
more appropriate than linear mixed models to assess the ex-
plained variance, and therefore, we examined the conjoint
association at one time point instead of over time.
Analyses were performed in IBM SPSS 22.0, using signif-
icance level of α=0.05.
Results
Sociodemographic and clinical characteristics
of respondents and non-respondents at T1
The questionnaire was completed by 73 % of survivors (n=
2625) at T1, 83 % (n=1643) at T2, and 82 % (n=1458) at T3.
Respondents at T1 were significantly younger, were more
often male, had a longer time since diagnosis, were more often
diagnosed with stage I disease, and were more often treated
with radiotherapy compared to non-respondents at T1 (all
p<0.05; data not shown). Furthermore, respondents at T1
more often received radiotherapy and were more often male
compared to survivors with unverifiable addresses at T1
(p<0.05; data not shown).
Differences between CRC survivors who completed one
or more than one questionnaire
CRC survivors who completed only one questionnaire were
older at time of first enrollment, were more often female, were
less likely to have a partner, were less likely to have a job,
were not meeting the physical activity guidelines, and were
more fatigued compared to those who completed two or more
questionnaires. In addition, they were more often diagnosed
with disease stage IV and, thus, less likely to receive radio-
therapy and surgery as primary treatment.
CRC survivors who completed only one or two question-
naires had a lower educational level and reported more comor-
bid conditions, more symptoms (anxiety, depression, pain),
less functioning (physical, role, emotional, cognitive, and so-
cial), and lower quality of life compared to those who com-
pleted all three questionnaires.
No differences were found in time since diagnosis, receiv-
ing chemotherapy in addition to surgery as primary treatment,
BMI, and insomnia (Table 1).
Factors longitudinally associated with CRF
Figure 3 shows that the CRF levels were relatively stable over
time. Mixed model analysis also showed no significant effect
of time (Table 2).
All sociodemographic factors were significantly associated
with CRF levels over time (Table 2). Male CRC survivors re-
ported, on average, 1.24 points lower levels of CRF than female
survivors. Furthermore, survivors ≤65 years of age reported, on
average, 0.62 points higher CRF levels compared to survivors
>65 years of age. CRC survivors who have a partner scored 0.82
points lower on CRF than survivors without a partner, and sur-
vivors with a high educational level score 1 point lower on CRF
compared to those with a medium or low educational level.
Regarding clinical characteristics, survivors who received
chemotherapy as primary treatment scored 0.86 points higher
on CRF compared to their counterparts. Survivors with two or
more comorbid conditions reported higher levels of CRF com-
pared to those with one (0.80 points) and no comorbid condi-
tions (1.63 points). BMI was positively associated with levels
of CRF (B=0.12). Years since diagnosis, disease stage, and
radiotherapy as primary treatment were not associated with
levels of CRF over time.
Significant between- and within-subject effects were found
for all well-being (social, emotional, cognitive functioning,
and global quality of life) and symptom factors (anxiety, de-
pression, pain, and insomnia).
In addition, significant between- and within-subject effects
were found for all functional status variables (physical and
role functioning,MVPA levels), except for occupational status
which was not related to CRF levels over time among CRC
survivors (Table 2).
Conjoint associations with CRF
At T1, 4 % of the differences in levels of CRF could be
explained by sociodemographic factors, 8 % by clinical fac-
tors, 59 % by behavior/well-being, and 37 % by functional
status. Of the behavior/well-being correlates, the highest var-
iance in CRF could be attributed to differences in levels of
depression (14 %), cognitive functioning (15 %), and global
quality of life (12 %). Of the functional status correlates, the
highest variance in CRF could be explained by physical
Support Care Cancer
Table 1 Sociodemographic and clinical characteristics of CRC survivors at T1
One wave N = 891 Two waves N = 281 Full response (three waves) N = 1453 p value
Sociodemographic characteristics
Sex 0.02
Male 458 (51 %) 157 (56 %) 833 (57 %)
Female 433 (49 %) 124 (44 %) 620 (43 %)
Age mean (SD) 71.3 (9.4) 69.4 (9.9) 68.2 (9.3) <0.001
Age (years) <0.001
≤ 65 234 (26 %) 85 (30 %) 536 (37 %)
> 65 657 (74 %) 196 (70 %) 917 (63 %)
Partner
Yes 626 (71 %) 222 (80 %) 1136 (79 %) <0.001
Educational level <0.001
Low 235 (27 %) 67 (24 %) 218 (15 %)
Middle 510 (59 %) 159 (58 %) 899 (62 %)
High 125 (14 %) 50 (18 %) 333 (23 %)
Clinical characteristics
Years since diagnosis mean (SD) 5.3 (2.8) 5.1 (2.8) 5.1 (2.8) 0.46
Years since diagnosis 0.55
≤ 5 514 (58 %) 170 (61 %) 828 (57 %)
> 5 377 (42 %) 111 (39 %) 625 (43 %)
Stage <0.001
I 262 (30 %) 77 (28 %) 441 (31 %)
II 335 (38 %) 101 (36 %) 511 (36 %)
III 220 (25 %) 86 (31 %) 418 (30 %)
IV 59 (7 %) 14 (5 %) 41 (3 %)
Chemotherapy
Yes 255 (29 %) 88 (31 %) 428 (30 %) 0.68
Radiotherapy
Yes 243 (27 %) 85 (30 %) 474 (33 %) 0.02
Surgery
Yes 872 (98 %) 279 (99 %) 1447 (99 %) <0.001
Number of comorbid conditions 0.01
None 192 (24 %) 61 (23 %) 361 (26 %)
One 208 (26 %) 69 (26 %) 432 (31 %)
Two or more 390 (49 %) 139 (52 %) 600 (43 %)
Comorbid conditions (yes)
Heart disease 176 (22 %) 53 (20 %) 234 (17 %) 0.01
Stroke 29 (4 %) 13 (5 %) 24 (2 %) 0.01
Hypertension 267 (34 %) 94 (35 %) 502 (36 %) 0.57
Asthma/COPD 104 (13 %) 40 (15 %) 123 (9 %) 0.001
Diabetes 128 (16 %) 52 (19 %) 176 (13 %) 0.004
Stomach disease 15 (2 %) 6 (2 %) 20 (1 %) 0.54
Kidney disease 41 (5 %) 19 (7 %) 40 (3 %) 0.001
Liver disease 34 (4 %) 19 (7 %) 25 (2 %) <0.001
Thyroid disease 49 (6 %) 12 (5 %) 56 (4 %) 0.07
Osteoarthritis 223 (28 %) 72 (27 %) 343 (25 %) 0.18
Rheumatoid arthritis 68 (9 %) 16 (6 %) 80 (6 %) 0.03
Back pain 223 (28 %) 66 (25 %) 378 (27 %) 0.50
BMI 26.6 (4.8) 26.5 (3.8) 26.8 (4.1) 0.41
Behavior/well-being
Anxiety (0–21) 4.9 (4.0) 5.1 (3.8) 4.4 (3.7) <0.001
Depressive symptoms (0–21) 5.3 (4.2) 4.6 (3.7) 3.8 (3.3) <0.001
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(17 %) and role functioning (15%). The total model explained
63 % of the variance in CRF levels.
Discussion
This study examined the course of CRF over time and its
correlates among CRC survivors using a model adapted from
a previously proposed conceptual framework. According to
our results, multiple factors were associated with CRF over
time: sociodemographic (sex, age, partner, educational level),
clinical (chemotherapy, comorbid conditions, BMI), behavior/
well-being (insomnia, pain, anxiety, depression, social, cogni-
tive, and emotional functioning), and functional status (phys-
ical and role functioning, being employed, physical activity).
The total model explained 63 % of the variance in CRF. The
differences in CRF levels could, for a large part, be attributed
to differences in behavior/well-being and functional status
and, to a lesser extent, sociodemographic and clinical charac-
teristics. The CRF levels were relatively stable over time, al-
though significant within-person effects were found for
behavior/well-being and functional status variables, which
could be due to disease progression. All demographic charac-
teristics were associated with levels of CRF, which is in ac-
cordance with the current literature and identifies groups at
high risk for CRF. Younger cancer survivors, females, and
lower educated survivors were more likely to feel fatigued
[20–22]. Survivors with a partner were less likely to be fa-
tigued, indicating the emotionally and instrumental supportive
role of social support in addressing CRF [23].
Several studies among short-term cancer survivors found
strong associations between clinical characteristics and levels
of CRF [20, 24]. Our study among longer-term cancer survi-
vors did not find significant temporal associations between
disease stage, type of primary treatment, time since diagnosis,
and levels of CRF, indicating that these factors become less
important over time. Nevertheless, we found that survivors
with two or more comorbid conditions were more likely to
feel fatigued than those with either only one or without co-
morbidity. Similarly, other studies have reported that increas-
ing numbers of comorbid conditions were associated with
CRF [25]. We previously found that comorbidity explained
a greater proportion of the variance in CRF scores among
cancer survivors than clinical or sociodemographic variables
[26].
Our results show that behavioral factors and well-being are
significantly associated with CRF levels over time, which is
consistent with previous literature demonstrating significant
influences of physical distress factors like pain and insomnia
and psychological distress factors like depression and anxiety
on CRF [27]. It may be that these symptoms arise through a
common pathway as previous research on inflammation and
CRF suggests that tumors and the treatments used to treat
them activate proinflammatory cytokines, leading to CRF
and other symptoms [28].
Several previously conducted studies found significant as-
sociations between physical fitness and physical activity and
levels of CRF among cancer survivors [27], which is in accor-
dance with our finding of a negative association between func-
tional status and CRF. Physical activity can counteract phys-
ical deconditioning and directly influence levels of CRF, or it
Table 1 (continued)
One wave N = 891 Two waves N = 281 Full response (three waves) N = 1453 p value
Pain (0–100) 18.1 (25.2) 18.0 (25.1) 15.2 (23.6) 0.01
Insomnia (0–100) 21.9 (29.8) 23.1 (29.1) 19.9 (27.6) 0.11
Social functioning (0–100) 85.3 (23.9) 84.0 (23.9) 87.6 (21.2) 0.01
Emotional functioning (0–100) 84.1 (20.8) 83.5 (20.1) 87.4 (18.2) <0.001
Cognitive functioning (0–100) 84.1 (20.5) 82.7 (22.2) 85.8 (19.9) 0.03
Global quality of life (0–100) 73.4 (21.1) 75.1 (18.1) 79.7 (17.6) <0.001
Functional status
Physical functioning (0–100) 75.1 (22.8) 78.0 (20.1) 83.1 (18.7) <0.001
Role functioning (0–100) 74.9 (29.9) 76.2 (28.6) 83.1 (25.3) <0.001
Occupation <0.001
Yes 82 (10 %) 51 (18 %) 280 (19 %)
Moderate or vigorous physical activity (h/week) 9.1 (8.9) 10.2 (8.4) 12.3 (9.0) <0.001
Meeting physical activity guidelines <0.001
Yes 664 (75 %) 239 (86 %) 1314 (91 %)
Mean cancer-related fatigue 21.8 (7.6) 21.7 (7.0) 19.9 (6.4) <0.001
Cancer-related fatigue <0.001
Yes 352 (43 %) 127 (46 %) 485 (34 %)
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can reduce CRF indirectly by its beneficial effects on mood,
immune functioning, or sleep [27].
Most sociodemographic characteristics remain stable over
time. On the other hand, behavioral/well-being factors and
functional status may be subject to change. Although the
CRF levels remained relatively stable over time in our study,
we did findwithin-subject effects for all behavioral/well-being
and functional status factors. This indicates that levels of CRF
can change by influencing these factors by means of
interventions. Some interventions have shown efficacy in re-
ducing CRF. Meta-analyses showed that psychosocial inter-
ventions (cognitive behavioral therapy, supportive-expressive
therapy, education/counseling, behavioral/relaxation therapy)
had a small to moderate effect on CRF [29–31], exercise in-
terventions had a near moderate effect in reducing CRF [29,
31–36], and pharmacological interventions with methylpheni-
date, a sympathomimetic psychostimulant, was more effective
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Fig. 3 Longitudinal changes in CRF over time for different correlates. Vertical axis represents CRF total scores (0–50); horizontal axis represents time
points (T1–T3)
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unclear which intervention (or combination of interventions)
is best for each individual. A factor that makes the treatment of
CRF complicated is that other symptoms such as pain, insom-
nia, and psychological distress frequently co-occur with CRF,
as our results also indicate. The exact mechanisms of this co-
occurrence are unclear: are all symptoms caused by cancer and
its treatment? Are high pain levels causing high CRF levels or
the other way around? And, which symptom(s) do we need to
treat? It can be hypothesized that survivors with high levels of
CRF and psychological distress will benefit most from a psy-
chosocial intervention, while survivors with lower physical fit-
ness will benefit from an exercise intervention. To personalize
treatment of CRF, it may be an option for future studies to take
a network approach. Instead of interpreting symptoms as a
function of a set of underlying/latent factors, the network ap-
proach conceptualizes symptoms as mutually interacting, often
reciprocally reinforcing elements of a complex network. Thus,
rather than interpreting symptoms as measurements of a latent
variable, symptoms are viewed as part of a causal system [38].
Table 2 Adjusted linear mixed models estimating the individual
associations between each independent variable and CRF over time
B 95 %CI p value
Time
T1 Ref Ref
T2 0.10 −0.15–0.35 0.44
T3 0.12 −0.13–0.38 0.34
Sociodemographic characteristics
Sex <0.001






Yes −0.82 −1.46 to −0.17
No Ref Ref
Educational level
Low 1.03 0.23–1.84 0.01
Middle 1.13 0.55–1.72 <0.001
High Ref Ref
Clinical characteristics




I −1.20 −3.01–0.61 0.20
II −0.83 −2.64–0.98 0.37




No −0.86 −1.72 to −0.01 0.05
Radiotherapy
Yes Ref Ref
No −0.44 −1.09–0.20 0.18
Number of comorbid conditions
None −1.63 −2.07 to −1.19 <0.001
One −0.80 −1.15 to −0.44 <0.001
Two or more Ref Ref
BMI 0.12 0.07–0,17 <0.001
Behavior/well-being
Pain
Between 0.15 0.14–0.17 <0.001
Within 0.03 0.03–0.04 <0.001
Insomnia
Between 0.10 0.09–0.11 <0.001
Within 0.02 0.01–0.03 <0.001
Social functioning
Between −0.21 −0.23 to −0.20 <0.001
Within −0.04 −0.05 to −0.03 <0.001
Table 2 (continued)
B 95 %CI p value
Emotional functioning
Between −0.23 −0.24 to −0.21 <0.001
Within −0.07 −0.08 to −0.06 <0.001
Cognitive functioning
Between −0.22 −0.23 to −0.21 <0.001
Within −0.06 −0.07–0.05 <0.001
Global quality of life
Between −0.27 −0.28 to −0.25 <0.001
Within −0.07 −0.08 to −0.06 <0.001
Anxiety
Between 1.04 0.97–1.12 <0.001
Within 0.50 0.43–0.57 <0.001
Depressive symptoms
Between 1.31 1.24–1.38 <0.001
Within 0.60 0.54–0.67 <0.001
Functional status
Physical functioning
Between −0.21 −0.23 to −0.20 <0.001
Within −0.08 −0.09 to −0.06 <0.001
Role functioning
Between −0.17 −0.18 to −0.16 <0.001
Within −0.05 −0.05 to −0.04 <0.001
Occupation
Yes Ref Ref
No 0.64 −0.21–1.51 0.14
Moderate to vigorous physical activity level
Between −0.14 −0.18 to −0.10 <0.001
Within −0.03 −0.05 to −0.01 <0.01
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These causal systems can be different for each individual de-
pending on centrality (which symptom is most important in
one’s network), connectivity (which symptoms are connected
and howwell are they connected), and distance (how long does
it take for one symptom to influence another symptom). By
studying the network of an individual cancer survivor, it be-
comes possible to target interventions at particular part of a
person’s network (e.g., the central symptom such as CRF) [39].
Some limitations of the present study should be mentioned.
First, although information was present regarding demograph-
ic and clinical characteristics of the respondents and non-re-
spondents, it remains unknown why non-respondents de-
clined to participate. In addition, the differences found be-
tween respondents and non-respondents limit the generaliz-
ability of our results. Second, although our study has a longi-
tudinal study design, it is still not possible to determine cau-
sality among the study variables, since the associations could
also be influenced by variables that were not measured in the
study. Further, we used the EORTC QLQ-C30 to assess dif-
ferent aspects of well-being; however, it could be argued that
some constructs (e.g., cognitive functioning) could better be
assessed with more specific questionnaires or even objective
measures. Because all participants were CRC survivors, we
can only generalize our results to this group of survivors. Last,
we assessed an adapted model, as we do not have biological
data. Nevertheless, this large population-based longitudinal
study with good response rates provides a comprehensive
view on several factors related to levels of CRF over time.
To conclude, this study showed that sociodemograpic and
clinical factors were associated with CRF levels over time
among CRC survivors; however, well-being, cancer-related
symptoms, and functional status explained a larger part of
the variance in levels of CRF.
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